ONCS - オンコセク・メディカル (OncoSec Medical Incorporated)

ONCSのニュース

   OncoSec Medical Inc Shares Close the Day 13.8% Higher - Daily Wrap  2022/01/14 07:30:28 Kwhen Finance
OncoSec Medical Inc (ONCS) shares closed today 13.8% higher than it did at the end of yesterday. The stock is currently down 10.3% year-to-date, down 86.7% over the past 12 months, and down 93.4% over the past five years. Today, the Dow Jones Industrial Average fell 0.5%, and the S&P 500 fell 1.4%. Trading Activity Shares traded as high as $1.07 and as low as $0.82 this week.Shares closed 88.0% below its 52-week high and 22.5% above its 52-week low.Trading volume this week was 26.8% lower than the 10-day average and 68.0% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.0. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 93.7% The company's stock price performance over the past 12 months lags the peer average by 116.2% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   OncoSec Announces Changes to its Board of Directors  2021/12/17 14:09:00 Benzinga
PENNINGTON, N.J. and SAN DIEGO , Dec. 17, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS ) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body''s immune system to target and attack cancer, today announced that Margaret Dalesandro , Ph.D., Chair of the Board of Directors and member of the Leadership Committee, has resigned from the Board of Directors and the Leadership Committee, effective immediately, and Dr. Linda Shi , M.D., Ph.D., has been added to the OncoSec Board of Directors and appointed Chair. Kevin Smith remarked, "On behalf of the Board of Directors, we are grateful to Margaret for her leadership, expert guidance, and commitment to the company, particularly over the last six months stepping into her active role on the Leadership Committee. We would like to thank Margaret for her dedication to the company." Dr. Linda Shi is the deputy president and Chief Medical officer of Grand Pharma ( China ), as well as an Executive Director of Grand Pharmaceutical Group Limited, a publicly listed company in Hong Kong .
   OncoSec Medical (NASDAQ:ONCS) Releases Quarterly Earnings Results  2021/12/16 19:00:41 Dakota Financial News
OncoSec Medical (NASDAQ:ONCS) released its quarterly earnings results on Tuesday. The biotechnology company reported ($0.25) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.37) by $0.12, Fidelity Earnings reports. Shares of ONCS traded up $0.01 during mid-day trading on Thursday, hitting $1.23. 4,172 shares of the company traded hands, compared to its []
   OncoSec Medical (NASDAQ:ONCS) Announces Earnings Results  2021/12/16 16:58:42 Dakota Financial News
OncoSec Medical (NASDAQ:ONCS) released its quarterly earnings results on Tuesday. The biotechnology company reported ($0.25) EPS for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.12, Fidelity Earnings reports. ONCS traded up $0.02 on Thursday, hitting $1.24. The company had a trading volume of 3,923 shares, compared to its average volume of 625,943. The […]
   State Street Corp Invests $56,000 in OncoSec Medical Incorporated (NASDAQ:ONCS)  2021/12/13 09:10:43 Dakota Financial News
State Street Corp purchased a new stake in shares of OncoSec Medical Incorporated (NASDAQ:ONCS) in the second quarter, HoldingsChannel reports. The institutional investor purchased 19,929 shares of the biotechnology companys stock, valued at approximately $56,000. Several other large investors also recently made changes to their positions in the company. Millennium Management LLC lifted its holdings []
   Flashy Stock: Snap Inc. (NYSE:SNAP), OncoSec Medical Incorporated (NASDAQ:ONCS)  2021/07/27 22:10:30 Stock Equity
Snap Inc. (NYSE:SNAP) with the stream of -3.37% also noticed, India OncoSec Medical Incorporated (NASDAQ:ONCS) encountered a rapid change of -3.15% in the last hour of Tuesdays trading session. Snap The post Flashy Stock: Snap Inc. (NYSE:SNAP), OncoSec Medical Incorporated (NASDAQ:ONCS) appeared first on Stocks Equity .
   The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts  2021/07/27 11:48:32 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 26) Absci, CORP (NASDAQ: ABSI ) (IPOed Thursday) Arvinas, Inc. (NASDAQ: ARVN ) BioNTech SE (NASDAQ: BNTX ) ( disclosed plans to make mRNA vaccine for malaria by 2022) Cassava Sciences, Inc. (NASDAQ: SAVA ) (announced positive data for SavaDx, an investigational diagnostic/biomarker to detect Alzheimer''s disease with a simple blood test) Eli Lilly and Company (NYSE: LLY ) Moderna, Inc. (NASDAQ: MRNA ) Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE ) NanoVibronix, Inc. (NASDAQ: NAOV ) (announced first shipment of its next generation pain management device, PainShield Plus) Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) Sight Sciences, Inc. (NASDAQ: SGHT ) (IPOed July 15) Translate Bio, Inc. (NASDAQ: TBIO ) (moved on positive analyst action) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 26) 23andMe Holding Co. (NASDAQ: ME ) AbCellera Biologics Inc.
   OncoSec to Participate in Fireside Chat at BTIG Virtual Biotechnology Conference  2021/07/26 12:30:00 PR Newswire
PENNINGTON, N.J. and SAN DIEGO, July 26, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced that Interim CEO and Chief Operating Officer, Brian Leuthner, and Senior Vice President, Chief Clinical Development Officer, Sandra Aung,
   Analysts Recommendations to Consider: McEwen Mining Inc. (NYSE:MUX), OncoSec Medical Incorporated (NASDAQ:ONCS)  2021/07/20 22:18:06 Stock Equity
McEwen Mining Inc. (NYSE:MUX) with the stream of 0.45% also noticed, India OncoSec Medical Incorporated (NASDAQ:ONCS) encountered a rapid change of -1.02% in the last hour of Tuesdays trading session. The post Analysts Recommendations to Consider: McEwen Mining Inc. (NYSE:MUX), OncoSec Medical Incorporated (NASDAQ:ONCS) appeared first on Stocks Equity .
   The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street  2021/07/20 12:19:55 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 19) Cytokinetics, Incorporated (NASDAQ: CYTK ) ( announced topline results from Cohorts 1 and 2 of the Phase 2 study of CK-274 in obstructive outflow disease in hypertrophic cardiomyopathy) Forward Pharma A/S (NASDAQ: FWP ) ResMed Inc. (NYSE: NRMD) Legend Biotech Corporation (NASDAQ: LEGN ) Moderna, Inc. (NASDAQ: MRNA ) ( extended gains on recent momentum) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 19) 4D pharma plc (NASDAQ: LBPS ) Adaptimmune Therapeutics plc (NASDAQ: ADAP ) Adverum Biotechnologies, Inc. (NASDAQ: ADVM ) Aerovate Therapeutics, Inc. (NASDAQ: AVTE ) (IPOed June 30) Agile Therapeutics, Inc. (NASDAQ: AGRX ) Allena Pharmaceuticals, Inc. (NASDAQ: ALNA ) Alzamend Neuro, Inc. (NASDAQ: ALZN ) Aptose Biosciences Inc. (NASDAQ: APTO ) ARCA biopharma, Inc. (NASDAQ: ABIO ) Ascendis Pharma A/S (NASDAQ: ASND ) Assembly Biosciences, Inc.
   OncoSec Aims to Treat Cancer with what the Body Makes Naturally — IL-12  2021/05/03 14:24:39 Benzinga
There’s no arguing that immunotherapies and immune checkpoint inhibitors have drastically improved cancer patients’ chances for survival. Checkpoint inhibitors are the most widely used immunotherapy and work by amplifying the immune system’s ability to fight cancer, with some remarkable success. However, the biotech company OncoSec (NASDAQ: ONCS ) believes that the power of immunotherapies has yet to be fully realized. Checkpoint inhibitors are intended to “block the off-switch” to the body’s T-cells to allow such cells to destroy cancers. Although it seems they’re most effective in “hot” or T-cell inflamed tumors, which have already been identified by the immune system as a target, as opposed to “cold” or immunologically devoid tumors that have not provoked an immune response. Here’s where OncoSec’s DNA gene transfer technology, TAVO™ (tavokinogene telseplasmid), comes in. “TAVO takes cold tumors, turns them hot and leverages drugs like Keytruda that allow T-cells to uncover and attack tumor cells.
   OncoSec Medical Earnings Report: Here’s what to expect from Stock market Insights & financial analysis  2021/03/11 14:02:00 Stock Market Daily
OncoSec Medical announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   OncoSec Announces Approval of $2.5 Million in NJEDA NOL Program Tax Benefits  2021/02/23 14:00:00 PR Newswire
PENNINGTON, N.J. and SAN DIEGO, Feb. 23, 2021 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (Nasdaq:ONCS), a late-stage biotechnology company focused on designing, developing and commercializing innovative therapies and proprietary medical approaches to stimulate and to guide…
   OncoSec Appoints Bridget O'Keeffe, Ph.D. as Vice President of Clinical Development  2021/02/18 13:30:00 PR Newswire
PENNINGTON, N.J. and SAN DIEGO, Feb. 18, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced the appointment of Bridget O'Keeffe, Ph.D., a biotech industry veteran with more than 15 years of experience, as Vice President of Clinical…
   OncoSec Announces First Subjects Dosed in Phase 1 Trial of CORVax12, OncoSec's COVID-19 Vaccine Candidate Combining Interleukin-12 (IL-12) with an Enhanced SARS-CoV-2 Spike Protein  2021/01/27 14:00:00 PR Newswire
PENNINGTON, N.J. and SAN DIEGO, Jan. 27, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) today announced that it has dosed several subjects in its Phase 1 clinical trial of CORVax12, the only vaccine candidate to include an immunostimulatory cytokine to address COVID-19….

calendar